Import from '@healthrx/components';

Praluent and Bupropion Interaction: What Patients and Clinicians Need to Know

The Short Answer: No Meaningful Interaction Between Praluent and Bupropion

Alirocumab and bupropion do not interact through any shared metabolic pathway. Alirocumab is a fully human IgG1 monoclonal antibody that is broken down by general protein catabolism throughout the body, bypassing the hepatic cytochrome P450 system entirely. Bupropion inhibits CYP2D6 and is itself primarily metabolized by CYP2B6, neither of which touches alirocumab.

The FDA label for alirocumab (Praluent) states explicitly that no cytochrome P450-mediated drug interactions are expected because the drug is not a substrate, inducer, or inhibitor of any CYP isoform. [1] Clinicians can therefore co-prescribe these two agents without pharmacokinetic concern.

Why Biologics Sit Outside the CYP Framework

Small-molecule drugs compete for CYP enzymes in the liver and intestinal wall. Monoclonal antibodies are far too large (roughly 150 kDa for IgG1) to enter hepatocytes in a way that engages CYP-mediated biotransformation. [2] Instead, they are internalized by cells throughout the body via endosomal uptake and cleaved into constituent amino acids, which are then recycled or excreted. This means the entire universe of CYP-based drug interactions, from CYP2D6 inhibition to CYP3A4 induction, is irrelevant to alirocumab dosing.

The same logic applies to other PCSK9 inhibitors such as evolocumab (Repatha). A 2021 review in Clinical Pharmacokinetics confirmed that no PCSK9 monoclonal antibody demonstrates CYP-mediated interactions in published pharmacokinetic studies. [3]

P-glycoprotein and Transporter Considerations

P-glycoprotein (P-gp) and OATP transporters govern the distribution of many small-molecule drugs. Alirocumab is not a substrate for P-gp, BCRP, OATP1B1, or OATP1B3. [1] Bupropion's interaction with these transporters is limited and clinically minor. There is no shared transporter pathway between these two drugs.

Understanding Bupropion's Pharmacology

Bupropion is an atypical antidepressant and smoking-cessation agent that works by inhibiting neuronal reuptake of dopamine and norepinephrine. It carries two pharmacologically relevant properties for drug-interaction assessment: CYP2D6 inhibition and a dose-dependent reduction in seizure threshold.

Bupropion as a CYP2D6 Inhibitor

Bupropion and its active metabolite hydroxybupropion are moderate-to-strong inhibitors of CYP2D6. [4] This is clinically significant when co-prescribing drugs that depend on CYP2D6 for either activation (e.g., tamoxifen, codeine) or clearance (e.g., metoprolol, tricyclic antidepressants, certain antipsychotics). The FDA label for bupropion (Wellbutrin SR/XL; Zyban) warns that co-administration with CYP2D6-metabolized drugs may require dose reduction of those agents. [4]

Because alirocumab is not metabolized by CYP2D6 or any other CYP enzyme, this inhibitory effect has no consequence for alirocumab plasma levels, receptor occupancy, or LDL-lowering efficacy.

Bupropion's Seizure Threshold Effect

Bupropion reduces the seizure threshold in a dose-dependent manner. The incidence of seizures with immediate-release bupropion at 300 mg/day is approximately 0.1%; that risk rises roughly tenfold at 600 mg/day. [4] This effect is intrinsic to bupropion's pharmacodynamic profile and is not worsened by alirocumab, which has no central nervous system pharmacodynamic activity.

Prescribers should maintain standard bupropion seizure precautions (keeping total daily dose at or below 450 mg; avoiding abrupt dose escalation; avoiding concurrent agents that independently lower seizure threshold such as antipsychotics and systemic corticosteroids) independent of whether alirocumab is part of the patient's regimen. [4]

Bupropion Metabolism via CYP2B6

Bupropion is primarily cleared by CYP2B6, which converts it to hydroxybupropion. [5] Alirocumab has no effect on CYP2B6 activity, so bupropion plasma concentrations are not altered by alirocumab co-administration. Patients switching to alirocumab from a lipid-lowering regimen that included a strong CYP2B6 inhibitor or inducer (e.g., stopping rifampin) should have bupropion levels reconsidered, but that is a separate clinical question unrelated to alirocumab itself.

Alirocumab's Clinical Profile and Why It Matters for Polypharmacy

Patients prescribed alirocumab typically carry a high burden of cardiovascular disease or familial hypercholesterolemia, meaning they are often on five to ten concurrent medications. Knowing that alirocumab is pharmacokinetically inert with respect to enzyme-based interactions simplifies polypharmacy management considerably.

ODYSSEY Outcomes Trial Data

The ODYSSEY OUTCOMES trial (N=18,924) evaluated alirocumab 75 mg or 150 mg every two weeks added to high-intensity statin therapy in patients with recent acute coronary syndrome. At a median follow-up of 2.8 years, alirocumab reduced major adverse cardiovascular events by 15% relative to placebo (HR 0.85; 95% CI 0.78-0.93; P<0.001). [6] The trial enrolled patients on a wide range of background medications, including antidepressants. No signal of interaction-related adverse events with concurrent psychiatric medications emerged in the safety database.

ODYSSEY LONG TERM LDL Data

ODYSSEY LONG TERM (N=2,341) demonstrated that alirocumab 150 mg every two weeks produced a mean LDL-C reduction of 61% from baseline versus 0.8% with placebo at 24 weeks (P<0.001). [7] Sustained LDL reductions of this magnitude are maintained without titration adjustments driven by co-medications, provided the underlying co-medication does not alter PCSK9 biology (none of the common psychiatric drugs do).

The ACC/AHA 2022 Guideline Position

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD whose LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe. If LDL-C level remains 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor." [8] That guidance does not restrict PCSK9 inhibitor use based on concurrent antidepressant therapy, and no psychiatric drug class appears on alirocumab's formal contraindication list.

Pharmacodynamic Overlap: Are There Any Shared Risks?

Pharmacodynamic interactions occur when two drugs affect the same physiological system in additive or antagonistic ways, even if they do not affect each other's plasma concentrations. Alirocumab and bupropion act on entirely different physiological systems: PCSK9-mediated LDL receptor recycling versus central monoamine reuptake. No shared pharmacodynamic pathway has been identified.

Injection Site and Systemic Immune Reactions

Alirocumab carries a small risk of injection-site reactions and hypersensitivity (reported in approximately 7.2% of patients in clinical trials). [1] Bupropion is not associated with potentiation of monoclonal antibody immunogenicity. Clinicians can counsel patients that any new rash, urticaria, or local reaction after an alirocumab injection should be evaluated on its own merits, not attributed to a bupropion interaction.

Cardiovascular Effects: A Nuanced Picture

Bupropion causes modest increases in blood pressure and heart rate, particularly at higher doses. A meta-analysis of 14 randomized controlled trials found mean systolic blood pressure increases of approximately 1.3 mmHg with bupropion versus placebo, with a somewhat larger effect at doses of 300 mg/day or more. [9] Alirocumab, by contrast, reduces cardiovascular events and has a neutral effect on blood pressure. The two agents do not amplify each other's hemodynamic effects. Clinicians managing patients with hypertension should monitor blood pressure per standard bupropion prescribing guidance, regardless of alirocumab use.

Clinical Decision Framework: Co-Prescribing Alirocumab and Bupropion

The following stepwise approach applies when a patient requires both a PCSK9 inhibitor and bupropion:

Step 1. Confirm the indication for each drug. Alirocumab is indicated for heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia (as an adjunct), or established ASCVD with inadequate LDL control on maximally tolerated statin therapy. [1] Bupropion is indicated for major depressive disorder, seasonal affective disorder, or smoking cessation (as Zyban). Verify neither indication overlaps or conflicts.

Step 2. Screen bupropion's actual drug interactions. The clinically relevant bupropion interactions involve CYP2D6 substrates (metoprolol, codeine, tamoxifen, certain antipsychotics) and CYP2B6 inducers/inhibitors (rifampin, ritonavir, carbamazepine). [4] Run a complete reconciliation against those drug classes. Alirocumab does not appear on that list.

Step 3. Set seizure risk parameters. Cap bupropion at 450 mg/day total; do not exceed 150 mg per dose for immediate-release formulations; avoid concurrent epileptogenic agents. [4] These precautions are the same whether or not alirocumab is on the medication list.

Step 4. Establish lipid monitoring. The ACC/AHA recommends a fasting lipid panel 4-12 weeks after initiating or adjusting PCSK9 inhibitor therapy, then every 3-12 months. [8] Bupropion does not affect LDL-C, HDL-C, or triglycerides in any clinically meaningful direction, so the standard monitoring schedule applies without modification.

Step 5. Counsel the patient. Patients often discover online references to "bupropion drug interactions" and become alarmed. A clear explanation that alirocumab bypasses the liver's enzyme system typically resolves that concern. Patients should report any new skin reactions near injection sites (alirocumab-specific) and any new or worsening seizures, mood changes, or blood pressure elevations (bupropion-specific) as two independent sets of surveillance parameters.

Monitoring Parameters When Both Drugs Are Prescribed

Lipid Panel Targets

The primary monitoring goal for alirocumab therapy is LDL-C. In high-risk ASCVD patients, the ACC/AHA and AACE both target LDL-C below 70 mg/dL, and many guideline-concordant practices target below 55 mg/dL in very-high-risk patients. [8] A baseline lipid panel before alirocumab initiation, with follow-up at 8-12 weeks, gives adequate data on response. Bupropion does not alter this measurement or confound interpretation of results.

Bupropion Therapeutic Considerations

Bupropion does not have a widely used plasma drug level target in routine clinical practice for most psychiatric indications, though CYP2D6 poor metabolizers (approximately 5-10% of European-ancestry populations) may accumulate higher levels of hydroxybupropion. [5] Genetic CYP2D6 testing is available and may be considered in patients with unexpected bupropion toxicity or lack of response, but this is unrelated to alirocumab co-prescription.

Injection Technique and Adherence

Alirocumab is administered subcutaneously every 2 weeks (75 mg or 150 mg) or every 4 weeks (300 mg). [1] Adherence to the injection schedule is the most important predictor of sustained LDL lowering. Patients on bupropion for smoking cessation may have recently quit tobacco use, which itself modestly lowers cardiovascular risk and may alter background statin response, but does not change alirocumab pharmacokinetics or dosing intervals.

Patient Counseling Points

Patients asking their pharmacist or clinician about the Praluent-bupropion combination deserve a direct, accurate answer rather than vague reassurance. Here are the specific points to cover:

• Praluent is broken down by your body's protein-recycling system, not by liver enzymes. Bupropion works on liver enzymes, so there is no overlap.
• Your LDL-lowering from Praluent will not be reduced because bupropion is on board.
• The maximum safe daily dose of bupropion is 450 mg; that rule does not change based on Praluent use.
• Report injection-site redness, swelling, or hives within 24 hours of any Praluent dose to your prescriber.
• Blood pressure checks remain important if you are on bupropion at doses of 300 mg/day or higher.
• Keep your PCSK9 inhibitor refills current. A gap in alirocumab dosing of more than 4 weeks can allow LDL to rebound toward baseline within approximately 2 weeks of the missed dose.

Special Populations

Patients With Renal Impairment

Alirocumab pharmacokinetics are not meaningfully altered by renal impairment based on population pharmacokinetic modeling across ODYSSEY trials. [1] Bupropion and its metabolites accumulate in severe renal impairment (eGFR <30 mL/min/1.73m²), requiring dose reduction. [4] This renal dose adjustment for bupropion is independent of alirocumab co-prescription.

Patients With Hepatic Impairment

Mild-to-moderate hepatic impairment does not significantly alter alirocumab exposure. [1] Bupropion is hepatically cleared and requires dose reduction in patients with Child-Pugh B or C cirrhosis. [4] Again, these are parallel but independent considerations; neither drug alters the other's hepatic handling.

Older Adults

Older patients (age 65 and above) represented approximately 24% of the ODYSSEY OUTCOMES population and showed consistent cardiovascular benefit from alirocumab without unique interaction signals. [6] Bupropion should be used cautiously in older adults given a modestly increased risk of seizures, falls, and blood pressure elevation with age; those are independent aging-related concerns, not concerns driven by alirocumab co-prescription.

Patients Who Are Pregnant or Planning Pregnancy

Alirocumab is not recommended during pregnancy given the physiological role of LDL in fetal development and absence of adequate human safety data. [1] Bupropion's use in pregnancy is associated with a debated risk of congenital heart defects at high doses; the FDA categorizes it as having complex benefit-risk considerations requiring individualized counseling. [4] If a patient on both drugs becomes pregnant, the decision to continue or discontinue either agent should be made based on each drug's individual risk profile, not on any interaction between them.

Frequently Asked Questions